Current Report Filing (8-k)
July 19 2021 - 7:49AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): July 19, 2021
CNS Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
Nevada
|
001-39126
|
82-2318545
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
2100 West Loop South, Suite 900
Houston,Texas 77027
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (800) 946-9185
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
___________________________
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading
Symbols(s)
|
Name
of each exchange on which registered
|
Common stock, par value $0.001 per share
|
CNSP
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01.
|
Regulation FD Disclosure.
|
Representatives of CNS Pharmaceuticals, Inc. (the
“Company”) will use the presentation set forth as Exhibit 99.1 herein in connection with various meetings from time to time
with the investment community.
The information contained in Item 7.01 of this
Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose
of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be deemed incorporated by reference in any
filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated
by reference..
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits
Signature
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CNS Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Chris Downs
|
|
|
|
Chris Downs
|
|
|
|
Chief Financial Officer
|
|
Dated: July 19, 2021
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Apr 2023 to Apr 2024